ADVANCES IN ONCOLOGY

We understand the urgency that cancer patients face. Our scientists are hard at work seeking to turn promising research into important medicines and making strides in innovative fields such as immuno-oncology as we build a pipeline of potential next-generation therapies so people with cancer may live longer, fuller lives.

IBRANCE® REACHES PATIENTS

We continue to invest in research at the forefront of developing new treatment options for people living with breast cancer. In early 2015, we received U.S. Food and Drug Administration accelerated approval for Ibrance® (palbociclib), in combination with letrozole, for the treatment of post-menopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2−) advanced breast cancer as initial endocrine-based therapy for their metastatic disease.

Ibrance has been approved in several other countries around the world based on results from the Phase 2 PALOMA-1 clinical trial. Results from the first Ibrance Phase 3 trial, PALOMA-3, were reported in 2015 and additional Phase 3 studies are ongoing. We filed a marketing application in Europe in mid-2015, and we have also initiated plans for additional global submissions in order to bring this innovative medicine to patients worldwide.

20,000
In the first 10 months following U.S. approval, Ibrance reached 20,000 patients.
Seeking Additional Indications

In addition to demonstrating efficacy in treating a relatively common type of metastatic breast cancer (ER+/HER2−), palbociclib is being tested in numerous clinical trials in other subsets of breast cancer and in other cancers such as head and neck cancer and pancreatic cancer, both on its own and in combination with other therapies.

The largest breast cancer trial for Ibrance to date, the PALbociclib CoLlaborative Adjuvant Study, or PALLAS, launched in August 2015. This Phase 3 trial for patients with early stage hormone receptor-positive (HR+)/HER2− breast cancer is designed to evaluate whether the addition of palbociclib to adjuvant endocrine therapy will improve disease-free survival and prevent the disease from recurring when compared with endocrine therapy alone (standard-of-care). A clinical research collaboration, the PALLAS trial is being conducted along with multiple research entities across Europe and other regions, including the Austrian Breast & Colorectal Cancer Study Group, Breast International Group, German Breast Group, National Surgical Adjuvant Breast and Bowel Project, PierceG, LLC and Alliance Foundation Trials, LLC. Approximately 4,600 people with early breast cancer are expected to enroll in the trial.

GLOBAL PARTNERSHIP TAKES ON METASTATIC BREAST CANCER

In a first-of-its-kind partnership, the Union for International Cancer Control and Pfizer have launched the SPARC initiative to encourage sustainable change for metastatic breast cancer (MBC) worldwide. SPARC stands for Seeding Progress and Resources for the Cancer Community. The program will support projects that address challenges in metastatic breast cancer by providing funding, mentorship and access to best practices to improve unmet needs for the global MBC patient population. The project topics range from raising awareness to addressing systematic gaps in health and public policies, patient access to information, and patient support, with the core focus being improving the lives of patients with MBC around the world. Ultimately, the SPARC initiative aims to empower advocacy groups, hospital networks, support groups and other organizations worldwide as they initiate projects to close the gap in information, support, awareness and policy between MBC and early disease, as well as help reduce the number of women diagnosed at the metastatic stage of breast cancer. From a large pool of 82 applicants from 46 countries, 20 organizations from 18 countries were selected to receive grants amounting to $760,000 (USD) in funding provided by Pfizer. The organizations will share progress and outcomes at the World Cancer Congress in 2016.
“Breast Cancer: A Story Half Told”

We have partnered with multiple breast cancer advocacy groups to chronicle the lives of women with metastatic breast cancer through the lenses of prominent photographers, in order to tell a fuller story of this poorly understood disease and its effects on patients, their families and the larger community we all share. This photo essay initiative is the next chapter of Breast Cancer: A Story Half Told, which was covered in the 2014 Annual Review. Its aim is to identify public misperceptions and gaps in knowledge surrounding metastatic breast cancer, the most advanced form of breast cancer.

The women profiled in this initiative are advocates, bloggers, working professionals, mothers, daughters and/or wives who have shared personal stories. A diverse group of breast cancer advocacy organizations provided counsel and support to bring these very human profiles to life. These include BreastCancer.org, Cancer Support Community, Living Beyond Breast Cancer, Metastatic Breast Cancer Network, and Young Survival Coalition. This photography-based effort encourages the public to share photos and messages of hope using the hashtag #StoryHalfTold, and is featured on the @StoryHalfTold Instagram, Facebook and Twitter accounts, as well as on www.StoryHalfTold.com.


“Pfizer is proud to be working with our advocacy partners and Story Half Told participants to dispel misperceptions, combat stigma and foster a more inclusive metastatic breast cancer conversation going forward.”
— Liz Barrett
President and General Manager, Pfizer Oncology
Global Status of Metastatic Breast Cancer: A Decade Report

In order to support the hundreds of thousands of women living with metastatic breast cancer around the world, we worked collaboratively with the European School of Oncology, within the scope of the Advanced Breast Cancer Third International Consensus Conference (ABC3), to release the Global Status of Metastatic Breast Cancer (MBC): A 2005–2015 Decade Report. This report was developed with guidance from a global steering committee of multidisciplinary leaders in the MBC community. The report is the most comprehensive analysis to date of the global landscape for advanced and metastatic breast cancer over the past decade and revealed both areas of improvement and substantial gaps in care, access to resources and support, and treatment outcomes for women with MBC.

In response to these findings, the European School of Oncology and members of the breast cancer community are calling for policymakers, advocates and the medical community to unite to develop a global charter as a call-to-action toward changing and improving MBC outcomes by the year 2025.


NO CURE YET

Global Status of Metastatic Breast Cancer (MBC): A 2005–2015 Decade Report found that 48%–76% of respondents from the general public in 14 countries believe that metastatic breast cancer is curable. However, there is currently no cure for metastatic disease.
We intend to be acknowledged leaders in the fight against cancer, developing medicines that provide meaningful impact and help to restore patient health and well-being. We look to bring these medicines to patients as quickly and safely as possible, and to establish their value so patients everywhere can access them. By bringing potentially life-changing therapies and support to patients, we aim to redefine life with cancer until we cure it.

Today we have eight approved cancer medicines, four of them launched in the last four years. Our large and growing investigational portfolio takes a multi-pronged attack on cancer, including drug candidates designed to kill tumor cells and immunotherapies designed to stimulate the immune system to mount a stronger defense against cancer. Research continues.

Our goal: launch at least one new cancer therapy each year from 2017 through 2022.

### BREAKTHROUGH THERAPY DESIGNATION FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

Our investigational antibody-drug conjugate, inotuzumab ozogamicin, received Breakthrough Therapy designation in the U.S. for the treatment of acute lymphoblastic leukemia (ALL). The designation was based on the results of the Phase 3 INO-VATE ALL trial, which compared inotuzumab ozogamicin to standard-of-care chemotherapy.
We are particularly encouraged by our growing strength and presence in immuno-oncology, with a broad investigational portfolio that spans numerous mechanisms of action. At the close of 2015, we had five immunotherapeutic agents in the clinic and plan to have up to 10 by the end of 2016. Key targets for these agents include PD-1, PD-L1, OX40, 4-1BB, CCR2 and Vaccine Based Immuno-therapy Regimen (VBIR) pathways that either stimulate or inhibit the immune system’s response to tumors.
## Immunotherapy Assets in the Clinic

<table>
<thead>
<tr>
<th><strong>Avelumab</strong></th>
<th><strong>Phase</strong></th>
<th><strong>Indication</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 3</td>
<td>Non-small cell lung cancer 1st line</td>
<td></td>
</tr>
<tr>
<td>Phase 3</td>
<td>Non-small cell lung cancer 2nd line</td>
<td></td>
</tr>
<tr>
<td>Phase 2 (Breakthrough Therapy, Fast Track and Orphan Drug Designations)</td>
<td>Metastatic Merkel cell carcinoma</td>
<td></td>
</tr>
<tr>
<td>Phase 3</td>
<td>Metastatic gastric/gastro-esophageal junction cancers 1st line</td>
<td></td>
</tr>
<tr>
<td>Phase 3</td>
<td>Metastatic gastric/gastro-esophageal junction cancers 3rd line</td>
<td></td>
</tr>
<tr>
<td>Phase 3</td>
<td>Platinum-resistant/refractory ovarian cancer</td>
<td></td>
</tr>
<tr>
<td>Phase 3</td>
<td>Locally advanced or metastatic urothelial cancer 1st line</td>
<td></td>
</tr>
<tr>
<td>Phase 1b</td>
<td>Advanced renal cell cancer</td>
<td></td>
</tr>
<tr>
<td>Phase 1</td>
<td>Non-small cell lung cancer</td>
<td></td>
</tr>
<tr>
<td><strong>4-1BB + CCR4 (in collaboration with Kyowa Hakko Kirin)</strong></td>
<td>Cancer</td>
<td></td>
</tr>
<tr>
<td><strong>CCR2</strong></td>
<td>Cancer</td>
<td></td>
</tr>
<tr>
<td><strong>OX40</strong></td>
<td>Cancer</td>
<td></td>
</tr>
<tr>
<td><strong>VBIR</strong></td>
<td>Prostate cancer</td>
<td></td>
</tr>
</tbody>
</table>
In 2015, avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody being co-developed with Merck KGaA, Darmstadt, Germany (Merck KGaA) was granted Orphan Drug designation in the U.S. and the EU, and Fast Track and Breakthrough Therapy designations in the U.S. for the treatment of metastatic Merkel cell carcinoma, a rare and aggressive type of skin cancer. If successful, the first potential commercial launch of avelumab is anticipated in 2017. As of December 31, 2015, the clinical development program for avelumab included more than 1,500 patients who had been treated across more than 15 tumor types, including breast cancer, gastric/gastro-esophageal junction cancers, head and neck cancer, Merkel cell carcinoma, melanoma, non-small cell lung cancer, ovarian cancer, renal cell carcinoma and urothelial (i.e., bladder) cancer. The alliance has initiated six pivotal trials, reaching its goal for 2015, with additional trials expected to initiate in 2016. Pfizer and Merck KGaA presented data from six studies evaluating the potential role of PD-L1 inhibition and avelumab’s safety and efficacy at the European Cancer Congress 2015.

Combination therapy holds perhaps the greatest potential within immuno-oncology. Our broad portfolio of immuno-oncology, small molecule and antibody-drug conjugate oncology assets affords us the opportunity to test a wide range of combination regimens on our own and with one of our current collaborators, Merck KGaA, and others. We continue to grow our footprint in immuno-oncology through such collaborations, including a CAR-T with Cellectis and Servier, and an IDO1 with iTEOS. Our collaboration with Kyowa Hakko Kirin to combine our 4-1BB with their anti-CCR4 antibody has already led to a Phase 1 study.

We believe our immuno-oncology portfolio, along with our skilled scientists and focused partnerships, should help enable Pfizer to be a formidable player in this vital, high opportunity area going forward.
BROADENING THE VACCINES PORTFOLIO

At Pfizer, we believe in the promise and value of vaccines to improve people’s lives. Leveraging leading technology in vaccine design and conjugation, we are pursuing preventative solutions to complex, difficult-to-treat bacterial pathogens — across the lifespan. We are also exploring the power of novel therapeutic vaccines to treat chronic conditions, and diseases such as cancer.

“We’re working on bringing our vaccines to more people everywhere they are needed. When I envision our world in 2030, I imagine one in which everyone — no matter where they’re born — has access to vaccines that help prevent illnesses and save lives.”

— Susan Silbermann
President, Pfizer Vaccines
Trumenba® is the first vaccine approved in the United States to protect against meningococcal meningitis serogroup B, and we are in the process of filing with regulatory authorities in other countries around the world.

Building Out Our Meningitis Vaccines Portfolio

During 2015, we acquired from GlaxoSmithKline two quadrivalent (ACWY) meningitis vaccines, Nimenrix® (meningococcal serogroups A, C, W-135 and Y conjugate vaccine) and Mencevax® (meningococcal polysaccharide serogroups A, C, Y and W-135 vaccine), currently marketed in a number of countries outside the U.S. In 2014, we acquired NeisVac-C® (meningococcal group C-TT conjugate vaccine, adsorbed) from Baxter, a vaccine for protection against serogroup C meningococcal disease, marketed primarily in Europe. With the addition of these complementary vaccines, we have created a comprehensive portfolio that is focused on helping to prevent meningococcal disease and for controlling outbreaks.

Trumenba® Supplied in Campus Outbreaks

In Trumenba’s first year of availability, we have already helped respond to outbreaks of serogroup B meningococcal meningitis at colleges and universities within the U.S. Following a public announcement by the Rhode Island State Department of Health that two students at Providence College contracted the disease, Pfizer worked with the college’s officials to supply the vaccine for the on-campus vaccination clinic. We delivered the doses in less than a day and supported more than fifty health care providers who administered them. At the University of Oregon, when four students were confirmed to have contracted the disease, it took us only one day to put together a unique partnership with two local pharmacy chains to ultimately supply mass vaccination events targeting more than 22,000 students.

“Pfizer colleagues jumped in at a moment’s notice to respond to these urgent public health situations. Thanks to the team’s focused actions, we helped to protect thousands of students from this rare but devastating disease.”

— John Schutta
Pediatric and Adolescent Lead, U.S. Vaccines
PREVNAR 13® REACHING ACROSS THE LIFESPAN

Our Prevnar franchise (known as Prevenar outside the U.S.) continues to expand. We recently manufactured our billionth dose. And with Prevnar 13® (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 Protein]) we are reaching more people, at more stages of life, around the world.

In 2014, the U.S. Centers for Disease Control and Prevention recommended Prevnar 13 for routine use to help protect adults age 65 and over against pneumococcal disease. Additional adult recommendations are under consideration by health authorities in countries around the world. We continue to work in close collaboration with global partners, such as the International Federation on Ageing, to raise awareness of the importance of adult vaccination.

Global Efforts to Reach People

We have pledged to supply up to 740 million doses of Prevenar 13® (pneumococcal polysaccharide conjugate vaccine, 13-valent, adsorbed) through 2025 to infants and young children throughout the developing world at a non-commercial price, through Gavi, the Vaccine Alliance.

Multi-Dose Vial for Prevenar 13®

To help address the practical constraints experienced by health workers operating in many Gavi countries, Pfizer has developed Prevenar 13® in a multi-dose vial (MDV) presentation and added the preservative 2 phenoxy ethanol to reduce vaccine wastage. The MDV presentation will contain four doses of Prevenar 13, and will be the same size as the current single dose vial. This will result in a smaller environmental footprint with a 75 percent reduction in cold chain and shipping material requirements. The dossier for the new MDV presentation is subject to approval by the European Medicines Agency and WHO prequalification. Pfizer’s ongoing investments to ensure high quality vaccines in adequate and reliable supply, as well as the first preserved PCV multi-dose vial presentation, will help ensure more children have access in communities whose health care systems are still developing.
INVESTIGATIONAL VACCINES ADVANCING IN PIPELINE

We have two prophylactic vaccines for hospital-acquired infections in Phase 2 trials, one to help prevent *Clostridium difficile* (*C. difficile*) disease and one to help prevent *Staphylococcus aureus* (*S. aureus*) infections. Both of these investigational vaccines have been granted Fast Track status by the U.S. Food and Drug Administration.

*C. difficile* is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Pfizer is currently investigating a vaccine that targets the two main disease-causing toxins produced by *C. difficile* (Toxin A & B) and initiated a Phase 2 clinical trial to investigate the safety, immunogenicity and tolerability of Pfizer’s *C. difficile* vaccine in healthy older adults.

*S. aureus* infections persist as a major cause of life-threatening hospital-acquired infections. To date, there is no licensed vaccine available to prevent invasive *S. aureus* disease. Our new investigational, multiantigen *S. aureus* vaccine is uniquely designed to help prevent a wide range of clinical disease manifestations by potentially facilitating pathogen killing at early stages of invasive infection.

“**The development of the *C. difficile* and *S. aureus* vaccines has real potential to reduce the suffering and mortality associated with bacterial infections contracted in health care settings. If successful, these vaccines would provide additional tools to positively impact human health.”**

— William Gruber, M.D.
Senior Vice President, Vaccine Clinical Research and Development

“**Vaccines generate tremendous social value by helping to prevent disease and sustain healthy communities.”**

— James Wassil
Global Health and Value Lead, Pfizer Vaccines

According to the U.S. Centers for Disease Control and Prevention, *S. aureus* results in nearly 700,000 hospitalizations and 11,000 deaths annually.
MATERNAL VACCINATION

To deliver on our promise to bring immunizations to people across all stages of life, we are exploring the development of maternal vaccination candidates to protect newborns from dangerous infections such as Group B streptococcus, respiratory syncytial virus, and cytomegalovirus (CMV), a herpes virus. Our acquisition of Redvax GmbH, a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, provides access to a preclinical human cytomegalovirus vaccine candidate, as well as intellectual property and a technology platform related to another vaccine program. The CMV vaccine program will complement our robust research portfolio of investigational vaccines and help place Pfizer among the leaders in CMV research and development.

The Institute of Medicine has ranked the development of a CMV vaccine as the highest priority because of the lives it would save and the disabilities it would prevent. A large segment of young adults, especially women of childbearing age who remain CMV negative, are at high risk of CMV infection during pregnancy and of passing the infection on to the unborn child (congenital infection). There are potentially serious and lifelong consequences for babies born with the disease. More children have disabilities due to congenital CMV than other well-known infections and syndromes, including Down syndrome, fetal alcohol syndrome, spina bifida and pediatric HIV/AIDS.

We are dedicated to developing innovative vaccines that help prevent and treat serious diseases. Through the acquisition of Redvax, we obtained an innovative CMV vaccine platform and expertise to develop a vaccine to prevent a difficult disease that can have a devastating and lifelong impact on young children.”

— Kathrin U. Jansen, Ph.D.
Senior Vice President, Head of Vaccine Research Development

I’M WORKING ON...

Kena Swanson
Senior Principal Scientist, Vaccine Research and Development
THE VALUE OF VACCINES

For every $1.00 the U.S. spends on childhood vaccinations,

$10.20 is saved in disease treatment costs.


THE IMPACT OF VACCINES ON INFECTIOUS DISEASE MORBIDITY IN THE UNITED STATES, PRE-VACCINES – 2014

The Impact of Vaccines on Infectious Disease Morbidity in the United States, Pre-vaccines-2014

<table>
<thead>
<tr>
<th>Disease</th>
<th>Diphtheria</th>
<th>H. influenzae</th>
<th>Invasive pneumococcal</th>
<th>Measles</th>
<th>Mumps</th>
<th>Pertussis</th>
<th>Polio</th>
<th>Rubella</th>
<th>Smallpox</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-vaccines</td>
<td>21,053*</td>
<td>20,000*</td>
<td>64,400*</td>
<td>530,217*</td>
<td>162,344*</td>
<td>200,752*</td>
<td>16,316*</td>
<td>47,745*</td>
<td>29,005*</td>
</tr>
<tr>
<td>Recent Reports of Cases in the US</td>
<td>1*</td>
<td>3,541*</td>
<td>15,356*</td>
<td>667*</td>
<td>1,223*</td>
<td>32,971*</td>
<td>0*</td>
<td>6*</td>
<td>0*</td>
</tr>
<tr>
<td>% Decrease</td>
<td>100%</td>
<td>82.3%</td>
<td>76%</td>
<td>99%</td>
<td>99%</td>
<td>83.6%</td>
<td>100%</td>
<td>99%</td>
<td>100%</td>
</tr>
</tbody>
</table>

* CDC Active Bacterial Core Surveillance Report, Emerging Infections Programs Network, Streptococcus pneumoniae, 1989
WE'RE WORKING ON
IMPROVING PEOPLE'S LIVES
THROUGH FOCUSED, COLLABORATIVE,
ACCELERATED R&D.

THERAPEUTIC AREAS OF FOCUS

We are advancing novel science and accelerating potential breakthrough therapies with the goal of delivering transformative medicines and vaccines, and possibly even cures, to patients in need. We focus our efforts in areas where we believe we are best positioned to utilize our expertise and bring unique, needed therapies to patients. More and more, our scientists are reaching into a dynamic R&D ecosystem to find the right partners to improve and accelerate our efforts. This focus and effort are helping to drive our long-term growth.
FOCUSING ON SCIENCE AND PATIENT IMPACT

ONCOLOGY

We’re investigating precision-guided therapies targeting novel signaling and epigenetic pathways, and cancer immunotherapies aimed at modulating the immune system.

I’M WORKING ON...

Puja Sapra
Senior Director, Oncology Research

Jeremy Bartlett
Associate Research Fellow, Drug Product Design

* Includes Hospira patents. Does not include licensed-in patents.
VACCINES

We are tackling some of the most deadly pediatric, adult and adolescent infectious diseases, as well as evaluating therapeutic vaccines across a variety of cancer types.

I'M WORKING ON...

Karin Joos
Senior Director, Biology, Vaccine Immunotherapeutics and Head of Cancer Vaccine Development

Alejandra Gurtman
Program Lead, Staph Aureus Vaccine

WATCH VIDEO
NEUROSCIENCE & PAIN

We are exploring Parkinson’s, Alzheimer’s and Huntington’s disease, as well as conducting research into trans-diagnostic domains, where we explore how cognition, anxiety and motivation correlate to the manifestation of a neuropsychiatric disorder, and their impact on a patient’s quality of life.

I’M WORKING ON...

Anabella Villalobos
Vice President, Neuroscience and Pain Medicinal Chemistry

David Gray
Senior Director, Parkinson's Drug Development Team Leader

I’M WORKING ON...

Matt Howe
Postdoctoral Research Fellow, Neuroscience Research Unit
CARDIOVASCULAR & METABOLIC

Our clinical-stage pipeline of potential therapies for patients covers a range of metabolic and cardiovascular risk factors, as well as exploring the areas of heart failure and nonalcoholic liver inflammation and damage.

I'M WORKING ON...

Albert Kim
Global Clinical Lead, Cardiovascular and Metabolic Disease

I'M WORKING ON...

Ann Marie Richard
Principal Scientist, Metabolic Disease

Pfizer's Legacy and Expertise in Cardiovascular Diseases
IMMUNOLOGY & INFLAMMATION

We are looking to transform the treatment of chronic inflammatory diseases such as rheumatoid arthritis and gastrointestinal disorders, while investigating potential therapies with application in medical dermatology.

I'M WORKING ON...

Iain Kilty
Senior Director, Rheumatology and Dermatology

Janet Buhllmann
Senior Principal Scientist, Immunology and Autoimmunity
RARE DISEASE

Our researchers in rare disease are working to unlock the scientific opportunity of gene therapy for people living with hemophilia, as well as investigating potential therapies for blood and neuromuscular diseases, which are devastating to patients, their families and the larger community.

I'M WORKING ON...

Joseph Nabhan
Principal Scientist, Rare Disease Research Unit

I'M WORKING ON...

Kena Swanson
Senior Principal Scientist, Vaccine Research and Development

BIOSIMILARS

With our acquisition of Hospira, we are now a leading global biosimilars company with a robust pipeline, best-in-class development capabilities and extensive real-world commercialization experience. We are working hard to extend that leadership by advancing high quality biosimilars to address the evolving needs of patients, payers and health systems.

I'M WORKING ON...

Lisa Skeens
Head of Global Regulatory Affairs, Global Established Pharma
EXPANDING THE R&D ECOSYSTEM

Our strategy looks to foster collaboration across the biomedical ecosystem to deliver innovation to patients. We are working to bring the best science, wherever it resides, into our efforts to find and develop needed therapies.

We attempt to establish flexible collaborations that can have an amplifying and accelerating effect — optimizing shared assets and capabilities and making it possible to pursue more research avenues or de-risking the earlier stage research that may provide the foundation for true medical breakthroughs. In these new forms of collaboration, we are sharing in the risks and rewards and attempting to expedite the pace of innovation and enhance the R&D ecosystem for the benefit of patients.

A HOLISTIC ECOSYSTEM FUELED BY COLLABORATION

- **BIOTECH / BIG PHARMA**: Access to Early and Late Stage Assets and Development Solutions
- **ACADEMIC PARTNERSHIPS**: Innovation through Cutting-Edge Science and Technology
- **PUBLIC PARTNERSHIPS**: Drug Discovery and Translational Medicine Innovation
- **PATIENT FOUNDATIONS**: Joint Funding for Shared Interests
- **VENTURE CAPITAL / EQUITY INVESTMENT**: Funding for Early Stage Products and Technologies
PIPELINE

Our pipeline from Phase 1 to registration includes 90 investigational therapies, which are focused in areas where we have the potential to bring differentiated, high value therapies and vaccines to patients faster.

PROGRAMS IN CLINICAL TRIALS OR REGISTRATION

Our clinical research activities are focused on translating novel science into therapies and vaccines. Today, our clinical pipeline includes targeted immunotherapies, which have the potential to be part of the next generation of cancer therapy; first-in-class vaccines with the potential to help prevent two deadly hospital-acquired infections; antibodies that may be potentially useful in treating lupus and inflammatory bowel disease; and, a potential new therapy for Parkinson’s disease. We are also applying our expertise in developing safe and effective biologic medicines to develop high quality biosimilars that may provide patients with access to alternative biologic therapies.
Pfizer Pipeline as of February 2, 2016

**I’M WORKING ON...**

**James Rusnak**  
Development Lead, Cardiovascular Metabolic Disease  
[WATCH VIDEO]

**Brenda Cooperstone**  
Vice President, Category Development Lead, Rare Disease  
[WATCH VIDEO]

**Lovisa Afzelius**  
Head of Computational Precision Medicine, Inflammation and Immunology  
[WATCH VIDEO]
Clinical trials and the people who participate in them play a vital and critical role in bringing new breakthroughs to society. Pfizer is committed to improving the effectiveness and efficiency of clinical trials, while protecting the safety, well-being and interests of clinical trial volunteers.

338 ACTIVE STUDIES
PATH 1-4 INVOLVING 60,870 ACTIVE PATIENTS ACROSS 9,191 SITES IN 66 COUNTRIES AS OF DECEMBER 2015
Mobile health applications, social media and health information technology offer new ways to capture data and insights from patients, enhance the patient experience, and coordinate the clinical trials conducted in partnership with thousands of independent researchers. We are seeing a rapid uptake in the use of mobile tools that may support participation and facilitate a larger breadth of clinical data.

We continue to expand our digital toolkit. Pfizer mClinical initiatives seek to improve the patient experience and provide investigators with advanced tools that streamline information access and maintain compliance using a flexible and modular approach. Modular components may include electronic informed consent, sensors and wearable tools, retention and visit reminders, video and remote visits, bring-your-own-device applications, electronic labels, and digital tools for clinical study start-up activities.

mCLINICAL — USING DIGITAL AND MOBILE TOOLS TO STREAMLINE THE PATIENT JOURNEY

Implementation of mobile clinical initiatives is done within existing legislative frameworks regarding the conduct of clinical trials, and laws regarding data privacy and medical devices.

Some of the initiatives below may only be available and occurring in the U.S.

1. **RECRUITMENT**
   - Digital tools to improve access to patients and facilitate study start-up

2. **SCREENING**
   - Investigator-facing inclusion/exclusion criteria screening tool

3. **CONSENT**
   - eConsent / re-Consent tools

4. **RETENTION AND COMPLIANCE**
   - Compliance toolkit including:
     - Medication reminders
     - Appointment tracking and reminders
     - Visit and dosing information
     - Study information and resources

5. **CONTINUOUS ENGAGEMENT AND TRACKING**
   - An evolving suite of tools including:
     - Electronic diaries
     - Sensor data capture from smartphones and devices
     - Patient-site communication tools
     - Integration with Pfizer Link (our program for clinical trial divers)
ONE PARTICIPANT’S EXPERIENCE WITH PFIZER LINK

Pfizer Link is a unique online patient tool and “alumni program” for study participants who have completed participation in a Pfizer-sponsored clinical trial (available in the U.S.) which patients have the option of consenting to participate in. Pfizer Link provides information on diseases and conditions of interest, suggestions and tools for disease management, general information about clinical trials, and access to study results including the Pfizer Blue Button Project (launched by the U.S. Departments of Veterans Affairs and Health and Human Services) for select studies to access individual electronic data. A participant in a recent Pfizer clinical trial said this about the value of joining the Pfizer Link community: “I joined the trial out of a desire to advance diabetes research, and had a satisfying experience as a research participant. After I completed the study, I joined Pfizer Link and Blue Button because I was curious about my clinical trial data, and because I wanted to have a community where I can participate and share my experiences. I look forward to learning more from Pfizer about breakthroughs in medical research and to identify other opportunities to participate in research and clinical trials.”

INVESTIGATING WITH INTEGRITY

We conduct all of our clinical trials to global standards for human subject research protection programs, comply with applicable laws and regulations, and fully protect the rights and welfare of trial participants. We integrate quality management principles into the clinical trial process, maintaining oversight over all trials, including those conducted for us by contract research organizations. To assure patient safety, data integrity, protocol adherence and good clinical practice regulatory compliance, clinical trial sites are monitored and subject to an audit program and the data generated in studies is subject to quality checks.

TRANSCELERATE® COLLABORATION DRIVING IMPROVEMENTS IN CLINICAL TRIALS

TransCelerate Biopharma has been a great industry collaboration success story. Founded to generate industry-wide efficiencies with an initial focus on clinical trials, its supporting membership has grown in just three years from 10 global pharmaceutical companies (including Pfizer) to 20. Its original five workstreams have grown to 14. The initial work that TransCelerate has delivered is being used to improve efficiency in clinical trials across the industry and across the world. The nonprofit consortium has created a comparator drug sourcing network, new data standards for several disease areas, mutual recognition for good clinical practice (GCP) training for approximately 200,000 investigators, a shared investigator registry (helping study investigators find research opportunities with sponsors), a model approach for removing identifiers from individual patient data in clinical studies, and, most recently, the Shared Investigator Platform — a single web portal for investigators with single sign-on regardless of whether the investigator is working on a study with Pfizer or any industry peer members.

“TransCelerate is an unprecedented collaboration amongst some of the world’s most successful biopharmaceutical companies,” said Dalvir Gill, Ph.D., TransCelerate’s CEO. “As one of TransCelerate’s founding members, Pfizer is committed to finding solutions to common drug development inefficiencies. Through this collaboration, we believe we can help transform the R&D landscape and implement solutions to drive efficient, effective and high quality delivery of new medicines to patients around the world.”

INVESTIGATORS WORLDWIDE HAVE RECEIVED RECOGNITION ACROSS THE CONSORTIUM FOR THEIR GCP TRAINING, REDUCING THE BURDEN ON INVESTIGATORS AND GIVING THEM BACK TIME TO SUPPORT PATIENTS AND STUDY PARTICIPANTS.
At Pfizer Consumer Healthcare, we have a passion to improve the lives of people around the world by empowering them to take health and wellness into their own hands. Our over-the-counter medicines, dietary supplements and personal care products are trusted brands for consumers around the world.

Caltrate® is the No. 1 selling brand of calcium supplements in the U.S. and China and is sold in 57 countries. In the U.S., no other leading brand offers a higher amount of vitamin D3 per tablet — which aids in the absorption of calcium. Caltrate 3-in-1 provides UC-II, a form of collagen, plus calcium, other minerals and vitamins D and C to support collagen production. Caltrate is available in four formulas and in a variety of forms to suit an individual’s needs.

Learn more at caltrate.com
**CENTRUM®**

Centrum® is the most doctor- and pharmacist-recommended multivitamin brand in the U.S., and the most preferred and most clinically-studied multivitamin brand in the world. Available in 86 countries, Centrum provides men, women and children a range of scientifically advanced multivitamins to help fill dietary gaps. Our latest innovation is Centrum VitaMints® — a multivitamin you enjoy like a mint for the on-the-go consumer.

Learn more at [centrum.com](http://centrum.com)

---

**CHAPSTICK®**

The leading lip care brand in the U.S., ChapStick® is sold in 25 countries. Consumers’ favorite ChapStick products include Moisturizer, Classic Cherry and Classic Original. With a history of more than 125 years, the brand continues to evolve, incorporating new technologies to meet consumer demands for a product that replenishes, rehydrates and protects lips while providing exciting flavors. We continue to refresh ChapStick through co-creation with our consumers — using their insights to take the product in new directions, such as ChapStick Total Hydration, a new line positioned in the beauty space.

Learn more at [chapstick.com](http://chapstick.com)
EMERGEN-C®

A leading health and wellness lifestyle brand, Emergen-C® is a vitamin supplement sold in more than 15 flavors, including its Original Formula, which is a drink mix that has 1,000 mg of vitamin C and other immune-supporting antioxidants such as zinc and manganese, seven B vitamins to enhance energy naturally, and electrolytes to replenish post-workout. Emergen-Zzzz® is a new product that includes melatonin to help you fall asleep naturally. In its more than 30 years on the market, Emergen-C has built a loyal customer base and has shown strong performance as a Pfizer brand.

Learn more at emergenc.com

NEXIUM® 24HR

Nexium® 24HR launched in the U.S. in mid-2014 and in a little over one year rose to become the leader in the U.S. over-the-counter heartburn relief category — an unprecedented achievement for a fourth-to-market product. Products for gastrointestinal conditions are the fourth largest global OTC category. We continue to launch Nexium OTC in countries around the world.

Learn more at nexium24hr.com

Nexium® is a registered trademark of AstraZeneca AB.
### ROBITUSSIN®

Robitussin® has been providing effective relief from cough and cold symptoms for more than 50 years. It is available in 41 countries and offers an extensive lineup of cough, cold, congestion and flu products for adults and children that can be taken during the day or at night.

Learn more at [robitussin.com](http://robitussin.com)

### THERMACARE®

Available in more than 20 countries, ThermaCare® Heatwraps deliver deep-penetrating heat that warms the muscles right where they hurt — to relax, soothe and unlock tight muscles. Portable and long-lasting, ThermaCare HeatWraps have transformed the field of heat therapy.

Learn more at [thermacare.com](http://thermacare.com)